(BDX) Becton Dickinson - Ratings and Ratios

Becton Dickinson and Company is a global medical technology company that develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products to various healthcare stakeholders. The companys product portfolio is diverse, with a presence in multiple segments, including medical, life sciences, and interventional.

The BD Medical segment is a significant contributor, offering a broad array of products, including vascular access technology, needle-free IV connectors, and medication safety systems. The company is a leader in the development of innovative solutions for IV therapy, medication management, and infection prevention. Its products are designed to improve patient outcomes, enhance clinician efficiency, and reduce healthcare costs.

The BD Life Sciences segment is another key area of focus, providing a range of products and services for specimen collection, blood culturing, and molecular testing. The companys fluorescence-activated cell sorters and analyzers are used in various research and clinical applications, including cancer diagnosis and immunotherapy. BD Life Sciences is also a leading provider of microbiology laboratory automation products and plated media products.

The BD Interventional segment offers a range of surgical products, including hernia repair solutions, biosurgery products, and peripheral intervention products. The companys urology and critical care products are designed to improve patient outcomes and simplify clinical workflows.

With a rich history dating back to 1897, Becton Dickinson has established itself as a trusted partner in the healthcare industry. The companys commitment to innovation, quality, and customer satisfaction has enabled it to maintain a strong market presence. As a leading player in the healthcare equipment industry, BDX is poised for continued growth, driven by its expanding product portfolio, increasing demand for healthcare services, and its global reach.

Analyzing the and , we can observe that BDX has experienced a decline in its stock price over the past year, with a 52-week low of $165.15 and a 52-week high of $247.95. The current price is $172.59, with a short-term moving average (SMA20) of $171.85, indicating a relatively stable trend. However, the longer-term moving averages (SMA50 and SMA200) are trending downward, suggesting a potential bearish outlook. The Average True Range (ATR) is 5.11, or 2.96%, indicating moderate volatility. From a fundamental perspective, the companys market capitalization is approximately $50 billion, with a P/E ratio of 33.79 and a forward P/E of 12.45. The Return on Equity (RoE) is 5.86%, indicating a relatively modest return on shareholder equity.

Forecasting future performance based on the available data, we can expect BDX to experience a gradual recovery in its stock price, driven by its continued innovation, expanding product portfolio, and growing demand for healthcare services. However, the companys high P/E ratio and relatively modest RoE may indicate potential headwinds. A potential trading strategy could involve buying BDX on dips, targeting a price range of $180-$200, with a stop-loss around $165. Conversely, a bearish outlook could involve shorting BDX, targeting a price range of $150-$160, with a stop-loss around $180.